Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs
Gilead is paying $10 million for sole ownership of arenaviral immunotherapies for hepatitis B (HBV) and HIV resulting from the company’s long-running collaboration with Hookipa Pharma.
Gilead is paying $10 million for sole ownership of arenaviral immunotherapies for hepatitis B (HBV) and HIV resulting from the company’s long-running collaboration with Hookipa Pharma.
